Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15283508 | 0.87 | ALDH1A1 (0.47) | PDK1ALDH1A1MAPK1RAB9AMAPT | |
| SCHEMBL27929922 | 0.87 | PDK1 (0.52) | PDK1ALDH1A1MAPK1MAPTTHRB | |
| SCHEMBL31585248 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MAPK1RAB9AMAPTTHRB | |
| SCHEMBL4063903 | 0.84 | ALDH1A1 (0.61) | ALDH1A1MAPK1RAB9AMAPTTHRB | |
| SCHEMBL29650091 | 0.84 | ALDH1A1 (0.61) | ALDH1A1MAPK1RAB9AMAPTTHRB | |
| SCHEMBL28218587 | 0.83 | ALDH1A1 (0.59) | ALDH1A1MAPK1RAB9AMAPTTHRB | |
| SCHEMBL532051 | 0.83 | MAPT (0.49) | PDK1ALDH1A1MAPK1RAB9AMAPT | |
| SCHEMBL30768275 | 0.82 | ALDH1A1 (0.46) | PDK1ALDH1A1MAPK1MAPTSMN1; SMN2 | |
| SCHEMBL25323753 | 0.80 | RAB9A (0.54) | ALDH1A1MAPK1RAB9AMAPTHPGD | |
| SCHEMBL29749825 | 0.80 | PDK1 (0.58) | PDK1ALDH1A1MAPK1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0365328-B1 | Pyridine derivatives | ZENECA LTD (GB) | 1996-04-03 | — | — | EP | claimed |
| US-5053415-A | Antiischemic, antiinflammatory, antiarthritic agents, cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-01 | — | — | US | claimed |
| EP-0365328-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1990-04-25 | — | — | EP | claimed |
| US-8263590-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-1660458-B1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| US-20110201606-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| US-7964592-B2 | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2011-06-21 | — | — | US | disclosed |
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
| EP-2287156-A1 | 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| EP-2275413-A1 | 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| EP-0365328-B1 | Pyridine derivatives | ZENECA LTD (GB) | 1996-04-03 | — | — | EP | disclosed |
| US-5053415-A | Antiischemic, antiinflammatory, antiarthritic agents, cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-01 | — | — | US | disclosed |
| EP-0365328-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1990-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | PDK1 854/4885ALDH1A1 587/4885MAPK1 2478/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | PDK1 830/4885ALDH1A1 647/4885MAPK1 2873/4885 |
| US-20110201606-A1 | PYRIMIDINE DERIVATIVES | DPYD, TYMP, TYMS | PDK1 254/4885ALDH1A1 955/4885MAPK1 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.